Animal Models of Parkinson's Disease: A Gateway to Therapeutics?
- 1 January 2014
- journal article
- review article
- Published by Elsevier in Neurotherapeutics
- Vol. 11 (1) , 92-110
Abstract
No abstract availableKeywords
This publication has 181 references indexed in Scilit:
- Adenosine A2A receptor gene disruption protects in an α‐synuclein model of Parkinson's diseaseAnnals of Neurology, 2011
- Toll-Like Receptor 4 Promotes α-Synuclein Clearance and Survival of Nigral Dopaminergic NeuronsThe American Journal of Pathology, 2011
- Lithium protects against oxidative stress‐mediated cell death in α‐synuclein‐overexpressing in vitro and in vivo models of Parkinson's diseaseJournal of Neuroscience Research, 2011
- Behavioral phenotyping of mouse models of Parkinson's diseaseBehavioural Brain Research, 2010
- Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disordersActa Neuropathologica, 2010
- Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's diseaseExperimental Neurology, 2009
- Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonismMovement Disorders, 2008
- In vivo alpha-synuclein overexpression in rodents: A useful model of Parkinson's disease?Experimental Neurology, 2008
- Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's diseaseExperimental Neurology, 2007
- Paraquat-induced Oxidative Stress in Drosophila melanogaster: Effects of Melatonin, Glutathione, Serotonin, Minocycline, Lipoic Acid and Ascorbic AcidNeurochemical Research, 2006